The results showed that SS subtype III had a significantly elevated T cell dysfunction score when compared with subtypes I and II, also suggest a distinct immune evasion strategy within SS subtype III and imply that patients with this subtype might exhibit greater responsiveness to therapeutic agents aimed at PD‐1 or PD‐L1 inhibition. This evidence concerns the gene CD274 and synovial sarcoma.